Active Ingredient(s): Infigratinib Phosphate
FDA Approved: * May 28, 2021
Pharm Company: * QED THERAP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Truseltiq Overview

Infigratinib, sold under the brand name Truseltiq, is an anti-cancer medication used to treat cholangiocarcinoma (bile duct cancer).[1][2] Infigratinib is a kinase inhibitor targeting the fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3[3][1][2] It was designated an orphan drug by the U.S. Food and Drug Administration (FDA) in 2019,[4] and it was approved for medical use in the United Stat...

Read more Truseltiq Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Truseltiq Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Infigratinib Phosphate
  • Capsule: 100mg, 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Infigratinib Phosphate or a similar ingredient: (1 result)